Aberrant activation of RAS/RAF/MEK/ERK signaling is frequently found in various cancers, due to genetic and epigenetic alterations, rendering them attractive therapeutic targets (Figure 1) [1,2,3]. Here, MAP2K7 is linked to cancer.